P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
377 Indexinhaled, 13
intravenous anaesthesia, 102 –103
nucleus, 90
perioperative supplementation, 355
stilboestrol, 16
straight lines with same gradient,61f
streptokinase, 344 –345
streptomycin, 319 –320
structure-activity relationships (SAR), 85
subcutaneous route, 12
sublingual route, 11
sucralfate, 296
sugars, 87
sulphation, 18 –19
sulphonylureas, 348 –349
kinetics, 349
mechanism of action, 349
side-effects, 349
uses, 349
summation drug interactions, 42
supraventricular tachyarrhythmias, 229 –237
with ventricular tachyarrhythmias, 239 –245
verapamil side-effects, 234 –235
suxamethonium, 17 , 179–184
cardiac output, 41
effects, 181 –184
genetic polymorphisms, 19
kinetics, 180
malignant hyperthermia, 182 –184
mechanism of action, 180
metabolism, 18 –19, 181f
presentation, 180
uses, 180
suxamethonium apnoea, 183 –184
sympathetic nervous system, 197 , 198f, 199
sympathomimetics, 197 –199, 216
direct-/indirect acting, 199
naturally occurring catecholamines,
199 –205
phosphodiesterase inhibitors
non-selective, 212 –214
selective, 214 –216
physiology, 197 –199
structure, 199 , 206f
synthetic agents, 205 –212
synergisms, 43
syringes, drug interactions, 40tachyarrhythmias, 229
atrioventricular nodal re-entrant tachycardia,
230f
tachyphylaxis, 38 –39
target-controlled infusion pumps (TCI), 76 ,
82 –84
decrement time, 83pumps, 83
safety, 83 –84
tautomerism, 45
tazobactam, 313
teicoplanin, 322 –323
temazepam, 273
tenoxicam, 158
teratogens, 16
terbutaline, 211
terminal elimination half-life, 71 , 77–78
tetanic stimulation, 178
therapeutic index, 75
thiazides, 98 , 305–307
effects, 306 –307
kinetics, 307
mechanism of action, 305
thiazolidinediones, 350 –351
thiocyanate (SCN), 246 –249
thiopentonal, 16 –17
thiopentone, 102 –107
effects, 105 –106
intra-arterial injection, 107
keto-enol transformation, 45
kinetics, 106
plasma,106f
presentation, 104
uses, 104
thioridazine, 284
three compartment models, 70 –71
thrombin, 336
thromboxane(s), 149 –151, 153
thromboxane A 2 (TXA 2 ), 335–336
thrombus formation, 335 –336
thyroid disease, 355 –358
thyroid hormones
feedback loops affecting production,356f
replacement, 355 –357
see alsotriiodothyronine (T 3 )
thyroxine (T 4 ), 216, 355–357
effects, 356
kinetics, 357
mechanism of action, 356
uses, 356
ticarcillin, 314 –315
ticlopidine, 337 –338
tight junctions, 1
time constant, 67 , 67f, 68, 74
natural logarithms, 58 –59
tinzaparin, 341 –342
tirofiban, 338
tissue binding of drugs, 72
tobramycin, 319 –320
tolbutamide, 348 –349
side-effects, 349
tolerance, 39